...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American journal of hospice and palliative care >A phase II study of hydrocodone for cough in advanced cancer.
【24h】

A phase II study of hydrocodone for cough in advanced cancer.

机译：氢可酮治疗晚期癌症的II期研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: Cough is a common symptom in advanced cancer. The use of hydrocodone as an antitussive has not been studied previously in this setting. This study evaluates hydrocodone for cough in advanced cancer METHODS: The results presented are from a phase II study with dose titration. Setting: Palliative medicine program in a tertiary referral center PATIENTS: 25 consecutive patients with cough from irreversible causes, on a stable opioid regimen for the prior 24 hours, and no previous or current use of hydrocodone for cough. INTERVENTION: 5 mg hydrocodone was administered twice daily. The dose was then titrated daily (maximum: 60 mg/24 h), if needed, until a > or = 50 percent improvement of the frequency of cough was achieved and then maintained for three consecutive days. MEASUREMENTS: Cough severity, frequency, complications, and hydrocodone side effects. RESULTS: 20 persons (10 women and 10 men) completed study evaluation. Median age was 63 years (range: 42-82). Nine patients had lung cancer and seven had lung or pleura metastases; 19 patients had at least 50 percent improvement of their cough frequency. The median best response was 70 percent improvement in the cough frequency (range: 50-90 percent). Median hydrocodone dose associated with the best response was 10 mg/day (range: 5-30 mg/day). Cough severity, frequency, associated symptoms and complications, and activities of daily living improved significantly. Side effects of hydrocodone (dry mouth, nausea, and drowsiness) were tolerable and rated as mild. CONCLUSIONS: Hydrocodone is effective and safe to treat cough in advanced cancer A starting dose of 10 mg per day in divided doses seems effective. Dose escalation may be required. Most improved within one day.
机译：目的：咳嗽是晚期癌症的常见症状。在这种情况下，以前尚未研究过使用氢可酮作为镇咳药。这项研究评估了氢可酮在晚期癌症中的咳嗽方法。方法：给出的结果来自剂量滴定的II期研究。地点：三级转诊中心的姑息治疗方案患者：连续25例因不可逆原因而咳嗽的患者，在过去24小时内采用稳定的阿片类药物治疗，并且以前没有或目前没有使用氢可酮进行咳嗽。干预：每天两次给予5 mg氢可酮。然后，如果需要的话，每天滴定剂量（最大剂量：60 mg / 24 h），直到咳嗽频率改善≥50％，然后连续三天维持。测量：咳嗽的严重程度，频率，并发症和氢可酮的副作用。结果：20人（10名女性和10名男性）完成了研究评估。中位年龄为63岁（范围：42-82岁）。 9名患者患有肺癌，7名患者患有肺或胸膜转移; 19名患者的咳嗽频率至少改善了50％。中位最佳反应是咳嗽频率改善70％（范围：50-90％）。与最佳疗效相关的氢可酮剂量中位数为10 mg /天（范围：5-30 mg /天）。咳嗽的严重程度，频率，相关症状和并发症以及日常生活活动得到了显着改善。氢可酮的副作用（口干，恶心和嗜睡）是可以忍受的，并被定为轻度。结论：氢可酮治疗晚期癌症的咳嗽是有效和安全的。分剂量每天10 mg的起始剂量似乎是有效的。可能需要增加剂量。一天之内改善最大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号